RAPP

insider transactions

Rapport Therapeutics, Inc. — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 30d

-18.6K

0 buy · 18.6K sell

Net value · 30d

-$743.8K

$0 in · $743.8K out

Sentiment · 30d

Net selling

0% buying · 100% selling

Open-market trades · 30d

0 buy · 18.6K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Grant·A
Jun 10, 26

Paul M Silva

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Wendy B. Young

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Ramiro Sanchez

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Robert J Perez

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Steven M Paul

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

John Maraganore

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

Reid M Huber

Director

$0

15.2K sh

Own New
Grant·A
Jun 10, 26

James Healy

Director

$0

15.2K sh

Own New
Sell·S
May 26, 26

Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC

10% Owner · 10b5-1

$743.8K

18.6K sh · $40.05

Own -0%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 10, 2026	Paul M Silva	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Wendy B. Young	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Ramiro Sanchez	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Robert J Perez	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Steven M Paul	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	John Maraganore	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	Reid M Huber	Director	Grant A	15.2K	New	—	$0
Jun 10, 2026	James Healy	Director	Grant A	15.2K	New	—	$0
May 26, 2026	Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10b5-1	10% Owner	Sell S	18.6K	-0%	$40.05	$743.8K

About RAPP insider trading

This page tracks insider transactions for Rapport Therapeutics, Inc. (RAPP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.